Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
USE OF TRICYCLIC COMPOUND
Document Type and Number:
WIPO Patent Application WO/2023/061434
Kind Code:
A1
Abstract:
The present invention provides a use of a compound represented by formula (A) or a pharmaceutically acceptable salt thereof in the preparation of drugs for treating cancer mediated by EGFR, FGFR2, KIT, ALK and/or ROS1 mutations. The compound has obvious inhibitory activity against cancer mediated by these mutation types.

More Like This:
WO/2011/078143PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
JP68719172- (Heta) aryl-substituted condensation bicyclic heterocyclic derivative as a pest control agent
JP3018442[Title of Invention] Heterocyclic compound
Inventors:
ZHENG SHANSONG (CN)
ZHENG QINGMEI (CN)
WANG MEI (CN)
DENG WEI (CN)
YANG YINGYING (CN)
ZHANG CHENWEI (CN)
Application Number:
PCT/CN2022/125057
Publication Date:
April 20, 2023
Filing Date:
October 13, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
QILU PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D487/04; A61K31/495; A61P35/00; C07D519/00
Domestic Patent References:
WO2021208918A12021-10-21
WO2020216371A12020-10-29
Foreign References:
CN101535276A2009-09-16
CN101616895A2009-12-30
Attorney, Agent or Firm:
MERITS IP LTD. (CN)
Download PDF:
View/Download PDF      PDF Help



 
Previous Patent: POLYMORPH OF EGFR INHIBITOR

Next Patent: OLEFIN CONVERSION CATALYST, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF